Latest practice-changing evidence, unveiling cutting-edge insights for the treatment of early and advanced stage renal cell carcinoma
Type
Webinaire
DÉTAILS DE L’ACTIVITÉ
Display Date
Monday March 18, 2024
Display Date Line 2
8 pm ET
Location
Virtual
Speaker
D. Heng, AK Lalani, M. Pavic & R. Rendon
CRÉDITS
Accreditation
Section 1 Group Learning Credits
Event Description
Speakers:
Adjuvant - Aly-Khan Lalani & Ricardo Rendon
Advanced - Daniel Heng & Michel Pavic
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Summarize the latest practice-changing evidence for the treatment of patients with early and advanced stage renal cell carcinoma.
- Engage in dynamic discussions of real-life patient cases, unraveling the intricacies of managing renal cell carcinoma.
- Discuss potential side effects and uncover state-of-the-art strategies to effectively manage novel combination therapies in advanced renal cell carcinoma, ensuring optimal patient outcomes.
Simultaneous interpretation from English to French will be available
Footer
ACCREDITATION
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
_______________________________________________________
Sponsored by:
